120 related articles for article (PubMed ID: 37105452)
1. Development of sensitive and robust multiplex digital PCR assays for the detection of ESR1 mutations in the plasma of metastatic breast cancer patients.
Corné J; Quillien V; Callens C; Portois P; Bidard FC; Jeannot E; Godey F; Le Du F; Robert L; Bourien H; Brunot A; Crouzet L; Perrin C; Lefeuvre-Plesse C; Diéras V; de la Motte Rouge T
Clin Chim Acta; 2023 May; 545():117366. PubMed ID: 37105452
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of ESR1 E380Q mutation in tumor tissue and plasma from Japanese breast cancer patients.
Takeshita T; Yamamoto Y; Yamamoto-Ibusuki M; Sueta A; Tomiguchi M; Murakami K; Omoto Y; Iwase H
BMC Cancer; 2017 Nov; 17(1):786. PubMed ID: 29166868
[TBL] [Abstract][Full Text] [Related]
3. Comparison of ESR1 Mutations in Tumor Tissue and Matched Plasma Samples from Metastatic Breast Cancer Patients.
Takeshita T; Yamamoto Y; Yamamoto-Ibusuki M; Tomiguchi M; Sueta A; Murakami K; Omoto Y; Iwase H
Transl Oncol; 2017 Oct; 10(5):766-771. PubMed ID: 28778025
[TBL] [Abstract][Full Text] [Related]
4. A single droplet digital PCR for ESR1 activating mutations detection in plasma.
Jeannot E; Darrigues L; Michel M; Stern MH; Pierga JY; Rampanou A; Melaabi S; Benoist C; Bièche I; Vincent-Salomon A; El Ayachy R; Noret A; Epaillard N; Cabel L; Bidard FC; Proudhon C
Oncogene; 2020 Apr; 39(14):2987-2995. PubMed ID: 32042112
[TBL] [Abstract][Full Text] [Related]
5. Droplet digital polymerase chain reaction assay for screening of ESR1 mutations in 325 breast cancer specimens.
Takeshita T; Yamamoto Y; Yamamoto-Ibusuki M; Inao T; Sueta A; Fujiwara S; Omoto Y; Iwase H
Transl Res; 2015 Dec; 166(6):540-553.e2. PubMed ID: 26434753
[TBL] [Abstract][Full Text] [Related]
6. ESR1 Gene Mutation in Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer Patients: Concordance Between Tumor Tissue and Circulating Tumor DNA Analysis.
Urso L; Vernaci G; Carlet J; Lo Mele M; Fassan M; Zulato E; Faggioni G; Menichetti A; Di Liso E; Griguolo G; Falci C; Conte P; Indraccolo S; Guarneri V; Dieci MV
Front Oncol; 2021; 11():625636. PubMed ID: 33777770
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of monitoring ESR1 mutations in circulating cell-free DNA in estrogen receptor positive breast cancer patients.
Takeshita T; Yamamoto Y; Yamamoto-Ibusuki M; Inao T; Sueta A; Fujiwara S; Omoto Y; Iwase H
Oncotarget; 2016 May; 7(22):32504-18. PubMed ID: 27102299
[TBL] [Abstract][Full Text] [Related]
8. The prevalence of estrogen receptor-1 mutation in advanced breast cancer: The estrogen receptor one study (EROS1).
Najim O; Huizing M; Papadimitriou K; Trinh XB; Pauwels P; Goethals S; Zwaenepoel K; Peterson K; Weyler J; Altintas S; van Dam P; Tjalma W
Cancer Treat Res Commun; 2019; 19():100123. PubMed ID: 30826563
[TBL] [Abstract][Full Text] [Related]
9. Sensitive Detection of Mono- and Polyclonal ESR1 Mutations in Primary Tumors, Metastatic Lesions, and Cell-Free DNA of Breast Cancer Patients.
Wang P; Bahreini A; Gyanchandani R; Lucas PC; Hartmaier RJ; Watters RJ; Jonnalagadda AR; Trejo Bittar HE; Berg A; Hamilton RL; Kurland BF; Weiss KR; Mathew A; Leone JP; Davidson NE; Nikiforova MN; Brufsky AM; Ambros TF; Stern AM; Puhalla SL; Lee AV; Oesterreich S
Clin Cancer Res; 2016 Mar; 22(5):1130-7. PubMed ID: 26500237
[TBL] [Abstract][Full Text] [Related]
10. A multiplex allele-specific real-time PCR assay for screening of ESR1 mutations in metastatic breast cancer.
Wang T; Liu JH; Zhang J; Wang L; Chen C; Dai PG
Exp Mol Pathol; 2015 Apr; 98(2):152-7. PubMed ID: 25746663
[TBL] [Abstract][Full Text] [Related]
11. Estrogen receptor mutations and splice variants determined in liquid biopsies from metastatic breast cancer patients.
Beije N; Sieuwerts AM; Kraan J; Van NM; Onstenk W; Vitale SR; van der Vlugt-Daane M; Dirix LY; Brouwer A; Hamberg P; de Jongh FE; Jager A; Seynaeve CM; Jansen MPHM; Foekens JA; Martens JWM; Sleijfer S
Mol Oncol; 2018 Jan; 12(1):48-57. PubMed ID: 29063679
[TBL] [Abstract][Full Text] [Related]
12.
Stergiopoulou D; Markou A; Tzanikou E; Ladas I; Makrigiorgos GM; Georgoulias V; Lianidou E
Cancers (Basel); 2021 Feb; 13(3):. PubMed ID: 33535614
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer: A Secondary Analysis of the BOLERO-2 Clinical Trial.
Chandarlapaty S; Chen D; He W; Sung P; Samoila A; You D; Bhatt T; Patel P; Voi M; Gnant M; Hortobagyi G; Baselga J; Moynahan ME
JAMA Oncol; 2016 Oct; 2(10):1310-1315. PubMed ID: 27532364
[TBL] [Abstract][Full Text] [Related]
14. Clinical relevance of circulating ESR1 mutations during endocrine therapy for advanced hormone-dependent endometrial carcinoma.
Drouyer A; Beaussire L; Jorda P; Leheurteur M; Guillemet C; Berghian A; Georgescu D; Di Fiore F; Perdrix A; Clatot F
BMC Cancer; 2023 Nov; 23(1):1061. PubMed ID: 37924026
[TBL] [Abstract][Full Text] [Related]
15. ESR1 mutations in HR+/HER2-metastatic breast cancer: Enhancing the accuracy of ctDNA testing.
Venetis K; Pepe F; Pescia C; Cursano G; Criscitiello C; Frascarelli C; Mane E; Russo G; Taurelli Salimbeni B; Troncone G; Guerini Rocco E; Curigliano G; Fusco N; Malapelle U
Cancer Treat Rev; 2023 Dec; 121():102642. PubMed ID: 37864956
[TBL] [Abstract][Full Text] [Related]
16. Mutation analysis using cell-free DNA for endocrine therapy in patients with HR+ metastatic breast cancer.
Sim SH; Yang HN; Jeon SY; Lee KS; Park IH
Sci Rep; 2021 Mar; 11(1):5566. PubMed ID: 33692409
[TBL] [Abstract][Full Text] [Related]
17. Development of multiplex digital PCR assays for the detection of PIK3CA mutations in the plasma of metastatic breast cancer patients.
Corné J; Le Du F; Quillien V; Godey F; Robert L; Bourien H; Brunot A; Crouzet L; Perrin C; Lefeuvre-Plesse C; Diéras V; De la Motte Rouge T
Sci Rep; 2021 Aug; 11(1):17316. PubMed ID: 34453076
[TBL] [Abstract][Full Text] [Related]
18. ESR1 and PIK3CA mutational status in serum and plasma from metastatic breast cancer patients: A comparative study.
Takeshita T; Yamamoto Y; Yamamoto-Ibusuki M; Tomiguchi M; Sueta A; Iwase H
Cancer Biomark; 2018; 22(2):345-350. PubMed ID: 29689710
[TBL] [Abstract][Full Text] [Related]
19. Clinical Implications of Monitoring ESR1 Mutations by Circulating Tumor DNA in Estrogen Receptor Positive Metastatic Breast Cancer: A Pilot Study.
Li X; Lu J; Zhang L; Luo Y; Zhao Z; Li M
Transl Oncol; 2020 Feb; 13(2):321-328. PubMed ID: 31877464
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of plasma cell-free DNA mutations in PIK3CA, AKT1, and ESR1 gene according to treatment lines in ER-positive breast cancer.
Takeshita T; Yamamoto Y; Yamamoto-Ibusuki M; Tomiguchi M; Sueta A; Murakami K; Iwase H
Mol Cancer; 2018 Feb; 17(1):67. PubMed ID: 29482551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
